Suppliers / Patheon France S.A.S

Patheon France S.A.S

United Arab Emirates 2 duplicate records merged Updated 9 July 2026

Patheon France S.A.S is a finished-dose manufacturer based in United Arab Emirates. It appears in 23 regulatory filings across 8 regulators, without an active US DMF or CEP on file. Its filings concentrate with JFDA (JO), DIGEMAPS (DO) and NPRA (MY). Its GMP standing is certified by MFDS (Korea), US FDA and NAFDAC (NG). Its most recent recorded inspection, by US FDA, closed on 29 September 2023 as VAI.

0
active US DMFs
0
valid CEPs
5
registered plants 1 with an FDA FEI number
23
filings across 8 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 29 September 2023 VAI US FDA
  • 27 September 2019 VAI US FDA
  • 8 June 2018 VAI US FDA
  • 11 March 2016 VAI US FDA
  • 28 March 2014 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Bourgoin-Jallieu, United Arab Emirates Not on file
Ontario, United Arab Emirates Not on file
Ferentino, United Arab Emirates Not on file
France, France 3004468553
Bourgoin-Jallieu, Nigeria Not on file

What they file, and where

Molecule Regulators Docs
Neostigmine Metilsulfate SFDA (Saudi Arabia) 1
Ponesimod SFDA (Saudi Arabia) 1
Pyridostigmine SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
JFDA (JO) 9 None
DIGEMAPS (DO) 4 None
NPRA (MY) 2 None
EDE (AE) 2 None
ARCSA (EC) 2 None
UZPHARM (UZ) 2 None
MFDS (Korea) None 12
US FDA None 1
NAFDAC (NG) None 1

Comparing suppliers?

Choose your molecules and target markets. Patheon France S.A.S comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 29 September 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates